PRN Ranibizumab verses continuous aflibercept in UK clinical practice
1 October 2018
| Jonathan Chan
|
Retina / Uvea / Vitreous
|
Age related macular degeneration, aflibercept, anti-VEGF therapy, ranibizumab
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
